Expression of Proteinopathies in Skin Biopsies of Patients With Neurodegenerative Disorders

Status: Recruiting
Location: See location...
Intervention Type: Diagnostic test
Study Type: Observational
SUMMARY

The goal of this observational study is to compare the aggregation pattern of proteinopathies (alpha-synuclein, amyloid-beta, phosphorylated tau and transactive response DNA -binding protein 43 \[TDP43\]) in skin biopsies of patients with a neurodegenerative disease like Alzheimer's disease, frontotemporal lobe dementia, Parkinson's disease, atypical Parkinsonism, amyotrophic lateral sclerosis or normal pressure hydrocephalus. The main question it aims to answer is: * Is there a specific pattern of aggregation of proteinopathies in skin biopsies in each neurodegenerative disease in comparison to healthy control subjects? Skin biopsies will be analyzed using immunohistochemistry and immunofluorescence for detection of alpha-synuclein, amyloid-beta, phosphorylated tau and TAR DNA binding protein 43, and the aggregation patterns will be compared between patients with a neurodegenerative disease vs patient with normal pressure hydrocephalus vs healthy control subjects.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 45
Healthy Volunteers: t
View:

• Patients 45 years and older

• Men and women

• Patients diagnosed with Alzheimer's disease, frontotemporal lobe dementia, Parkinson's disease, atypical Parkinsonism, amyotrophic lateral sclerosis or normal pressure hydrocephalus

• Patients that voluntarily accept to participate in the study and accept the consent form

• People 45 years and older

• Men and women

• Subjects can be related to a patient but not by blood (for example spouse of a patient)

• Subjects don't have direct family history of a neurodegenerative control

• Subjects don't have any clinical findings suggesting dementia

• Subjects voluntarily accept to participate in the study and accept the consent form

Locations
Other Locations
Mexico
Hospital Central Dr. Ignacio Morones Prieto
RECRUITING
San Luis Potosí City
Contact Information
Primary
Ildefonso Rodríguez-Leyva, MD PhD
ilrole@yahoo.com.mx
+52 444 834 2739
Backup
Cristina Monzón Tapia, MD
a267473@alumnos.uaslp.mx
Time Frame
Start Date: 2023-12-20
Estimated Completion Date: 2026-11-01
Participants
Target number of participants: 40
Treatments
Patients with neurodegenerative disease
Patients diagnosed with either Alzheimer's disease, frontotemporal lobe dementia, Parkinson's disease, atypical Parkinsonism or amyotrophic lateral sclerosis.
Patients with normal pressure hydrocephalus
Patients diagnosed with normal pressure hydrocephalus, because of their clinical presentation (acute or subacute gait abnormalities, memory loss or personality changes and urinary incontinence) with radiological confirmation of ventriculomegaly and normal cerebrospinal fluid opening pressure.
Healthy control subjects
Person, men or women, above 45 years old, that don't have history of family or personal neurodegenerative disease.
Sponsors
Collaborators: Hospital Central Dr. Ignacio Morones Prieto
Leads: Universidad Autonoma de San Luis Potosí

This content was sourced from clinicaltrials.gov